Malignant Mesothelioma
📧 Sign up to get email alerts when something new happens for Malignant Mesothelioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors [Phase 1]
Phase I study of IAG933 in patients with malignant mesothelioma and other solid tumors is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Immune Microenvironment and Gene Expression Profiling in Mesothelioma
A clinical trial update describes a study evaluating the immune microenvironment and gene expression profiling in mesothelioma, focusing on …
-
CLINICAL_TRIALS research · 2025-08-27Clinical Trial Update: Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Gavo-cel (TC-210), a mesothelin-targeted therapy, in patients with advanced mesothelin-expressing cancer…
-
CLINICAL_TRIALS research · 2025-08-20Clinical Trial Update: Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Iparomlimab and Tuvonralimab in combination with chemotherapy for malignant mesothelioma; the study is…
-
CLINICAL_TRIALS trial_result · 2025-07-23Clinical Trial Update: NM32-2668 in Adult Patients With Selected Advanced Solid Tumors [Phase 1]
A Phase 1 trial of NM32-2668 in adults with selected advanced solid tumors has been terminated. The study enrolled multiple tumor types incl…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: A Study of Sacituzumab Govitecan in People With Mesothelioma [Phase 2]
Phase 2 clinical trial evaluating Sacituzumab Govitecan for mesothelioma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-29Clinical Trial Update: CART-meso Long-term Follow-up
Clinical trial update reporting long-term follow-up data for subjects treated with lentiviral-based CART-meso therapy in mesothelioma, provi…
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study. [Phase 2]
This Phase 2 trial assesses the feasibility of an early palliative care intervention for patients with metastatic cancer. The study has comp…
-
CLINICAL_TRIALS research · 2025-06-11Clinical Trial Update: Pembrolizumab in Treating Patients With Malignant Mesothelioma [Phase 2]
Phase 2 trial evaluating pembrolizumab in malignant mesothelioma and related subtypes; the study is active but not recruiting.
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: HTL0039732 in Participants With Advanced Solid Tumours [Phase 1, Phase 2]
HTL0039732 is being evaluated in a Phase 1/2 study for multiple advanced solid tumours and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-05Clinical Trial Update: Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide [Phase 1]
Phase I dose-escalation study of azacitidine in combination with temozolomide in soft tissue sarcoma and mesothelioma has completed with res…
-
CLINICAL_TRIALS research · 2025-05-31Clinical Trial Update: First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma [Phase 2]
Phase 2 trial evaluating first-line sintilimab in combination with anlotinib and platinum doublet chemotherapy for malignant pleural mesothe…
-
EMA approval · 2025-05-28EMA Authorised: Pemetrexed medac (pemetrexed) — medac Gesellschaft für klinische Spezialpräparate mbH
EMA authorised medac's pemetrexed medicine for use in non-small cell lung cancer and malignant mesothelioma.
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Niraparib Efficacy in Patient With Unresectable Mesothelioma [Phase 2]
Phase 2 clinical trial update shows Niraparib efficacy in a patient with unresectable malignant mesothelioma.
-
CLINICAL_TRIALS research · 2025-05-15Clinical Trial Update: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]
Clinical trial update for Tulmimetostat DZR123 (CPI-0209) in adults with advanced solid tumors and various lymphomas. The study is in Phase …
-
CLINICAL_TRIALS research · 2025-05-06Clinical Trial Update: Olaparib in Patients With HRD Malignant Mesothelioma [Phase 2]
Olaparib is being evaluated in a Phase 2 trial for patients with malignant mesothelioma exhibiting homologous recombination deficiency; the …
-
CLINICAL_TRIALS research · 2025-04-27Clinical Trial Update: First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis. [NA]
Clinical trial assessing first local anesthesia thoracoscopy for diagnosing pleural effusion in patients with suspected malignant lung disea…
-
CLINICAL_TRIALS trial_result · 2025-02-20Clinical Trial Update: Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients [EARLY_Phase 1]
Early-phase 1 clinical trial evaluating heated intraperitoneal chemotherapy with doxorubicin and cisplatin for pediatric abdominal/pelvic tu…
-
EMA approval · 2025-02-12EMA Authorised: Pemetrexed Fresenius Kabi (pemetrexed) — Fresenius Kabi Deutschland GmbH
The EMA authorised Pemetrexed Fresenius Kabi (pemetrexed) for use in non-small cell lung cancer and malignant mesothelioma.
-
CLINICAL_TRIALS trial_result · 2025-02-03Clinical Trial Update: Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers [Phase 1]
Phase 1 study of cosibelimab (CK-301) as a single-agent therapy in adults with advanced cancers; the trial status is active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2024-12-09Clinical Trial Update: Dendritic Cell Vaccination for Patients with Solid Tumors [Phase 1, Phase 2]
Phase 1/Phase 2 clinical study evaluating a dendritic cell vaccine in patients with solid tumors, including glioblastoma and renal cell carc…
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: Exercise to Boost Immunity in Advanced Cancer [NA]
A clinical trial is evaluating whether an exercise program can boost immune response in patients with malignant mesothelioma, lung cancer, o…
-
EMA withdrawal · 2024-11-06EMA Withdrawn: Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) — Sandoz GmbH
The European Medicines Agency has withdrawn Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) from the European market. It was indica…
-
CLINICAL_TRIALS trial_result · 2024-10-26Clinical Trial Update: Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma [Phase 1]
Phase 1 study of intra-pleural GL-ONC1, a genetically modified vaccinia virus, in patients with malignant pleural effusion including mesothe…
-
EMA withdrawal · 2024-10-17EMA Withdrawn: Ciambra (pemetrexed disodium hemipentahydrate) — Menarini International Operations Luxembourg S.A.
EMA withdrew Ciambra (pemetrexed disodium hemipentahydrate) from the European market on 17 August 2022, with indications for non-small cell …